DrugPatentWatch Database Preview
Drugs in Development Information for SJG-136
» See Plans and Pricing
What is the drug development status for SJG-136?
SJG-136 is an investigational drug.
There have been 4 clinical trials for SJG-136.
The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2010.
The most common disease conditions in clinical trials are Fallopian Tube Neoplasms, Leukemia, Myeloid, and Syndrome. The leading clinical trial sponsors are National Cancer Institute (NCI) and [disabled in preview].
Summary for SJG-136
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 91 |
| WIPO Patent Applications | 196 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2010-07-01) |
| Vendors | 18 |
Recent Clinical Trials for SJG-136
| Title | Sponsor | Phase |
|---|---|---|
| SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin | National Cancer Institute (NCI) | Phase 2 |
| SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia | National Cancer Institute (NCI) | Phase 1 |
| SJG-136 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery | National Cancer Institute (NCI) | Phase 1 |
Clinical Trial Summary for SJG-136
Top disease conditions for SJG-136
Top clinical trial sponsors for SJG-136
US Patents for SJG-136
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
